This report aims to provide a comprehensive presentation of the global market for Cancer Antibody Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Antibody Drug Conjugates. This report contains market size and forecasts of Cancer Antibody Drug Conjugates in global, including the following market information:
Global Cancer Antibody Drug Conjugates Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cancer Antibody Drug Conjugates Market Sales, 2018-2023, 2024-2029, (K Dose)
Global top five Cancer Antibody Drug Conjugates companies in 2022 (%)
The global Cancer Antibody Drug Conjugates market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
First & Second Generation ADCs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Antibody Drug Conjugates manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Antibody Drug Conjugates Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Type, 2022 (%)
First & Second Generation ADCs
Third Generation ADCs
Global Cancer Antibody Drug Conjugates Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Cancer Antibody Drug Conjugates Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Antibody Drug Conjugates revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cancer Antibody Drug Conjugates revenues share in global market, 2022 (%)
Key companies Cancer Antibody Drug Conjugates sales in global market, 2018-2023 (Estimated), (K Dose)
Key companies Cancer Antibody Drug Conjugates sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Antibody Drug Conjugates, market overview.
Chapter 2: Global Cancer Antibody Drug Conjugates market size in revenue and volume.
Chapter 3: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cancer Antibody Drug Conjugates capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cancer Antibody Drug Conjugates Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Antibody Drug Conjugates Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Antibody Drug Conjugates Overall Market Size
2.1 Global Cancer Antibody Drug Conjugates Market Size: 2022 VS 2029
2.2 Global Cancer Antibody Drug Conjugates Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cancer Antibody Drug Conjugates Sales: 2018-2029
3 Company Landscape
3.1 Top Cancer Antibody Drug Conjugates Players in Global Market
3.2 Top Global Cancer Antibody Drug Conjugates Companies Ranked by Revenue
3.3 Global Cancer Antibody Drug Conjugates Revenue by Companies
3.4 Global Cancer Antibody Drug Conjugates Sales by Companies
3.5 Global Cancer Antibody Drug Conjugates Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cancer Antibody Drug Conjugates Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cancer Antibody Drug Conjugates Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Players in Global Market
3.8.1 List of Global Tier 1 Cancer Antibody Drug Conjugates Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Antibody Drug Conjugates Market Size Markets, 2022 & 2029
4.1.2 First & Second Generation ADCs
4.1.3 Third Generation ADCs
4.2 By Type - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
4.2.1 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2018-2023
4.2.2 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2024-2029
4.2.3 By Type - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
4.3 By Type - Global Cancer Antibody Drug Conjugates Sales & Forecasts
4.3.1 By Type - Global Cancer Antibody Drug Conjugates Sales, 2018-2023
4.3.2 By Type - Global Cancer Antibody Drug Conjugates Sales, 2024-2029
4.3.3 By Type - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
4.4 By Type - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cancer Antibody Drug Conjugates Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
5.2.1 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2018-2023
5.2.2 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2024-2029
5.2.3 By Application - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
5.3 By Application - Global Cancer Antibody Drug Conjugates Sales & Forecasts
5.3.1 By Application - Global Cancer Antibody Drug Conjugates Sales, 2018-2023
5.3.2 By Application - Global Cancer Antibody Drug Conjugates Sales, 2024-2029
5.3.3 By Application - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
5.4 By Application - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Cancer Antibody Drug Conjugates Market Size, 2022 & 2029
6.2 By Region - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
6.2.1 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2018-2023
6.2.2 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2024-2029
6.2.3 By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
6.3 By Region - Global Cancer Antibody Drug Conjugates Sales & Forecasts
6.3.1 By Region - Global Cancer Antibody Drug Conjugates Sales, 2018-2023
6.3.2 By Region - Global Cancer Antibody Drug Conjugates Sales, 2024-2029
6.3.3 By Region - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Cancer Antibody Drug Conjugates Revenue, 2018-2029
6.4.2 By Country - North America Cancer Antibody Drug Conjugates Sales, 2018-2029
6.4.3 US Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.4.4 Canada Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.4.5 Mexico Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Cancer Antibody Drug Conjugates Revenue, 2018-2029
6.5.2 By Country - Europe Cancer Antibody Drug Conjugates Sales, 2018-2029
6.5.3 Germany Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.4 France Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.5 U.K. Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.6 Italy Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.7 Russia Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.8 Nordic Countries Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.5.9 Benelux Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Cancer Antibody Drug Conjugates Revenue, 2018-2029
6.6.2 By Region - Asia Cancer Antibody Drug Conjugates Sales, 2018-2029
6.6.3 China Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.6.4 Japan Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.6.5 South Korea Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.6.6 Southeast Asia Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.6.7 India Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Cancer Antibody Drug Conjugates Revenue, 2018-2029
6.7.2 By Country - South America Cancer Antibody Drug Conjugates Sales, 2018-2029
6.7.3 Brazil Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.7.4 Argentina Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, 2018-2029
6.8.3 Turkey Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.8.4 Israel Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.8.5 Saudi Arabia Cancer Antibody Drug Conjugates Market Size, 2018-2029
6.8.6 UAE Cancer Antibody Drug Conjugates Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Cancer Antibody Drug Conjugates Major Product Offerings
7.1.4 Novartis Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Cancer Antibody Drug Conjugates Major Product Offerings
7.2.4 Merck Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Cancer Antibody Drug Conjugates Major Product Offerings
7.3.4 Roche Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 AbbVie
7.4.1 AbbVie Company Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Cancer Antibody Drug Conjugates Major Product Offerings
7.4.4 AbbVie Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.4.5 AbbVie Key News & Latest Developments
7.5 UCB
7.5.1 UCB Company Summary
7.5.2 UCB Business Overview
7.5.3 UCB Cancer Antibody Drug Conjugates Major Product Offerings
7.5.4 UCB Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.5.5 UCB Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Major Product Offerings
7.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Stem CentRx
7.7.1 Stem CentRx Company Summary
7.7.2 Stem CentRx Business Overview
7.7.3 Stem CentRx Cancer Antibody Drug Conjugates Major Product Offerings
7.7.4 Stem CentRx Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.7.5 Stem CentRx Key News & Latest Developments
7.8 Biogen Idec
7.8.1 Biogen Idec Company Summary
7.8.2 Biogen Idec Business Overview
7.8.3 Biogen Idec Cancer Antibody Drug Conjugates Major Product Offerings
7.8.4 Biogen Idec Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.8.5 Biogen Idec Key News & Latest Developments
7.9 Nordic Nanovector
7.9.1 Nordic Nanovector Company Summary
7.9.2 Nordic Nanovector Business Overview
7.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Major Product Offerings
7.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.9.5 Nordic Nanovector Key News & Latest Developments
7.10 Millennium
7.10.1 Millennium Company Summary
7.10.2 Millennium Business Overview
7.10.3 Millennium Cancer Antibody Drug Conjugates Major Product Offerings
7.10.4 Millennium Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.10.5 Millennium Key News & Latest Developments
7.11 Biotest AG
7.11.1 Biotest AG Company Summary
7.11.2 Biotest AG Cancer Antibody Drug Conjugates Business Overview
7.11.3 Biotest AG Cancer Antibody Drug Conjugates Major Product Offerings
7.11.4 Biotest AG Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.11.5 Biotest AG Key News & Latest Developments
7.12 PDL BioPharma
7.12.1 PDL BioPharma Company Summary
7.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Business Overview
7.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.12.5 PDL BioPharma Key News & Latest Developments
7.13 Progenics Pharmaceuticals
7.13.1 Progenics Pharmaceuticals Company Summary
7.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Business Overview
7.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Major Product Offerings
7.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.13.5 Progenics Pharmaceuticals Key News & Latest Developments
7.14 Seattle Genetics
7.14.1 Seattle Genetics Company Summary
7.14.2 Seattle Genetics Business Overview
7.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Major Product Offerings
7.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.14.5 Seattle Genetics Key News & Latest Developments
7.15 Viventia Biotechnologies
7.15.1 Viventia Biotechnologies Company Summary
7.15.2 Viventia Biotechnologies Business Overview
7.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Major Product Offerings
7.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.15.5 Viventia Biotechnologies Key News & Latest Developments
7.16 AbGenomics Corporation
7.16.1 AbGenomics Corporation Company Summary
7.16.2 AbGenomics Corporation Business Overview
7.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Major Product Offerings
7.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.16.5 AbGenomics Corporation Key News & Latest Developments
7.17 Helix BioPharma
7.17.1 Helix BioPharma Company Summary
7.17.2 Helix BioPharma Business Overview
7.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2018-2023)
7.17.5 Helix BioPharma Key News & Latest Developments
8 Global Cancer Antibody Drug Conjugates Production Capacity, Analysis
8.1 Global Cancer Antibody Drug Conjugates Production Capacity, 2018-2029
8.2 Cancer Antibody Drug Conjugates Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Antibody Drug Conjugates Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Antibody Drug Conjugates Supply Chain Analysis
10.1 Cancer Antibody Drug Conjugates Industry Value Chain
10.2 Cancer Antibody Drug Conjugates Upstream Market
10.3 Cancer Antibody Drug Conjugates Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Antibody Drug Conjugates Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Cancer Antibody Drug Conjugates in Global Market
Table 2. Top Cancer Antibody Drug Conjugates Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Cancer Antibody Drug Conjugates Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Cancer Antibody Drug Conjugates Revenue Share by Companies, 2018-2023
Table 5. Global Cancer Antibody Drug Conjugates Sales by Companies, (K Dose), 2018-2023
Table 6. Global Cancer Antibody Drug Conjugates Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Cancer Antibody Drug Conjugates Price (2018-2023) & (USD/Dose)
Table 8. Global Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 9. List of Global Tier 1 Cancer Antibody Drug Conjugates Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2018-2023
Table 15. By Type - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2024-2029
Table 16. By Application ? Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2018-2023
Table 20. By Application - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2024-2029
Table 21. By Region ? Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2018-2023
Table 25. By Region - Global Cancer Antibody Drug Conjugates Sales (K Dose), 2024-2029
Table 26. By Country - North America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Cancer Antibody Drug Conjugates Sales, (K Dose), 2018-2023
Table 29. By Country - North America Cancer Antibody Drug Conjugates Sales, (K Dose), 2024-2029
Table 30. By Country - Europe Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Cancer Antibody Drug Conjugates Sales, (K Dose), 2018-2023
Table 33. By Country - Europe Cancer Antibody Drug Conjugates Sales, (K Dose), 2024-2029
Table 34. By Region - Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Cancer Antibody Drug Conjugates Sales, (K Dose), 2018-2023
Table 37. By Region - Asia Cancer Antibody Drug Conjugates Sales, (K Dose), 2024-2029
Table 38. By Country - South America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Cancer Antibody Drug Conjugates Sales, (K Dose), 2018-2023
Table 41. By Country - South America Cancer Antibody Drug Conjugates Sales, (K Dose), 2024-2029
Table 42. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, (K Dose), 2018-2023
Table 45. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, (K Dose), 2024-2029
Table 46. Novartis Company Summary
Table 47. Novartis Cancer Antibody Drug Conjugates Product Offerings
Table 48. Novartis Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck Cancer Antibody Drug Conjugates Product Offerings
Table 52. Merck Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 53. Merck Key News & Latest Developments
Table 54. Roche Company Summary
Table 55. Roche Cancer Antibody Drug Conjugates Product Offerings
Table 56. Roche Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 57. Roche Key News & Latest Developments
Table 58. AbbVie Company Summary
Table 59. AbbVie Cancer Antibody Drug Conjugates Product Offerings
Table 60. AbbVie Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 61. AbbVie Key News & Latest Developments
Table 62. UCB Company Summary
Table 63. UCB Cancer Antibody Drug Conjugates Product Offerings
Table 64. UCB Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 65. UCB Key News & Latest Developments
Table 66. Bristol-Myers Squibb Company Summary
Table 67. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Offerings
Table 68. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 69. Bristol-Myers Squibb Key News & Latest Developments
Table 70. Stem CentRx Company Summary
Table 71. Stem CentRx Cancer Antibody Drug Conjugates Product Offerings
Table 72. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 73. Stem CentRx Key News & Latest Developments
Table 74. Biogen Idec Company Summary
Table 75. Biogen Idec Cancer Antibody Drug Conjugates Product Offerings
Table 76. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 77. Biogen Idec Key News & Latest Developments
Table 78. Nordic Nanovector Company Summary
Table 79. Nordic Nanovector Cancer Antibody Drug Conjugates Product Offerings
Table 80. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 81. Nordic Nanovector Key News & Latest Developments
Table 82. Millennium Company Summary
Table 83. Millennium Cancer Antibody Drug Conjugates Product Offerings
Table 84. Millennium Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 85. Millennium Key News & Latest Developments
Table 86. Biotest AG Company Summary
Table 87. Biotest AG Cancer Antibody Drug Conjugates Product Offerings
Table 88. Biotest AG Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 89. Biotest AG Key News & Latest Developments
Table 90. PDL BioPharma Company Summary
Table 91. PDL BioPharma Cancer Antibody Drug Conjugates Product Offerings
Table 92. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 93. PDL BioPharma Key News & Latest Developments
Table 94. Progenics Pharmaceuticals Company Summary
Table 95. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Offerings
Table 96. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 97. Progenics Pharmaceuticals Key News & Latest Developments
Table 98. Seattle Genetics Company Summary
Table 99. Seattle Genetics Cancer Antibody Drug Conjugates Product Offerings
Table 100. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 101. Seattle Genetics Key News & Latest Developments
Table 102. Viventia Biotechnologies Company Summary
Table 103. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Offerings
Table 104. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 105. Viventia Biotechnologies Key News & Latest Developments
Table 106. AbGenomics Corporation Company Summary
Table 107. AbGenomics Corporation Cancer Antibody Drug Conjugates Product Offerings
Table 108. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 109. AbGenomics Corporation Key News & Latest Developments
Table 110. Helix BioPharma Company Summary
Table 111. Helix BioPharma Cancer Antibody Drug Conjugates Product Offerings
Table 112. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 113. Helix BioPharma Key News & Latest Developments
Table 114. Cancer Antibody Drug Conjugates Production Capacity (K Dose) of Key Manufacturers in Global Market, 2021-2023 (K Dose)
Table 115. Global Cancer Antibody Drug Conjugates Capacity Market Share of Key Manufacturers, 2021-2023
Table 116. Global Cancer Antibody Drug Conjugates Production by Region, 2018-2023 (K Dose)
Table 117. Global Cancer Antibody Drug Conjugates Production by Region, 2024-2029 (K Dose)
Table 118. Cancer Antibody Drug Conjugates Market Opportunities & Trends in Global Market
Table 119. Cancer Antibody Drug Conjugates Market Drivers in Global Market
Table 120. Cancer Antibody Drug Conjugates Market Restraints in Global Market
Table 121. Cancer Antibody Drug Conjugates Raw Materials
Table 122. Cancer Antibody Drug Conjugates Raw Materials Suppliers in Global Market
Table 123. Typical Cancer Antibody Drug Conjugates Downstream
Table 124. Cancer Antibody Drug Conjugates Downstream Clients in Global Market
Table 125. Cancer Antibody Drug Conjugates Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Cancer Antibody Drug Conjugates Segment by Type in 2022
Figure 2. Cancer Antibody Drug Conjugates Segment by Application in 2022
Figure 3. Global Cancer Antibody Drug Conjugates Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cancer Antibody Drug Conjugates Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Cancer Antibody Drug Conjugates Revenue, 2018-2029 (US$, Mn)
Figure 7. Cancer Antibody Drug Conjugates Sales in Global Market: 2018-2029 (K Dose)
Figure 8. The Top 3 and 5 Players Market Share by Cancer Antibody Drug Conjugates Revenue in 2022
Figure 9. By Type - Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 11. By Type - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 12. By Type - Global Cancer Antibody Drug Conjugates Price (USD/Dose), 2018-2029
Figure 13. By Application - Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 15. By Application - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 16. By Application - Global Cancer Antibody Drug Conjugates Price (USD/Dose), 2018-2029
Figure 17. By Region - Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 20. By Region - Global Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 21. By Country - North America Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 22. By Country - North America Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 23. US Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 28. Germany Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 29. France Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 37. China Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 41. India Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 43. By Country - South America Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 44. Brazil Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales Market Share, 2018-2029
Figure 48. Turkey Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2018-2029
Figure 52. Global Cancer Antibody Drug Conjugates Production Capacity (K Dose), 2018-2029
Figure 53. The Percentage of Production Cancer Antibody Drug Conjugates by Region, 2022 VS 2029
Figure 54. Cancer Antibody Drug Conjugates Industry Value Chain
Figure 55. Marketing Channels
